Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
Status:
Completed
Trial end date:
2020-02-22
Target enrollment:
Participant gender:
Summary
This study has been designed as a multicentre, randomised, double-blind study of AVT02 in
healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02
compared to EU-Humira and US licenced Humira (US-Humira), when administered as a single 40 mg
SC dose.